



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/86, 5/10, A61K 48/00	A2	(11) International Publication Number: WO 00/08194
		(43) International Publication Date: 17 February 2000 (17.02.00)
<p>(21) International Application Number: PCT/GB99/02547</p> <p>(22) International Filing Date: 3 August 1999 (03.08.99)</p> <p>(30) Priority Data: 9816856.0 3 August 1998 (03.08.98) GB</p> <p>(71) Applicant (for all designated States except US): NEUROVEX LIMITED [GB/GB]; Marquis House, 67-68 Jermyn Street, London SW1Y 6NY (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): COFFIN, Robert, Stuart [GB/GB]; UCL Medical School, Division of Pathology, Department of Molecular Pathology, The Windeyer Building, 46 Cleveland Street, London W1P 6DP (GB). LATCHMAN, David, Seymour [GB/GB]; UCL Medical School, Division of Pathology, Department of Molecular Pathology, The Windeyer Building, 46 Cleveland Street, London W1P 6DP (GB).</p> <p>(74) Agents: WOODS, Geoffrey, Corlett et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
(54) Title: CELL LINES FOR THE PROPAGATION OF MUTATED HERPES VIRUSES		
(57) Abstract		
<p>A process for propagating a mutant herpes virus having a mutation in its endogenous HSV VP16 gene or a homologue thereof, which process comprises infecting a cell line with the mutant herpes virus and culturing the cell line, wherein the cell line comprises a nucleic acid sequence encoding a functional herpes simplex virus (HSV) VP16 polypeptide, or a homologue thereof, operably linked to a control sequence permitting expression of the polypeptide in said cell line; the nucleic acid sequence being (i) capable of complementing the endogenous gene and (ii) unable to undergo homologous recombination with the endogenous gene. In addition, the present invention provides cell lines which can be used for the growth of mutant herpes viruses which have defects in certain immediate early genes together with mutations in VP16 or homologue thereof.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

CELL LINES FOR THE PROPAGATION OF MUTATED HERPES VIRUSES

Field of the Invention

5 The present invention relates to cell lines used for the growth of mutant herpes viruses. It particularly relates to the growth of viruses with mutations in genes which are essential structural proteins, but which also have other functions the inactivation of which impairs virus growth. The invention provides cell lines giving enhanced growth of viruses with such inactivating mutations in a manner in which the inactivated function in the virus cannot be repaired by homologous recombination of viral sequences with the complementing
10 sequences in the cell line. In addition, the present invention also provides cell lines which can be used for the growth of mutant herpes viruses which have defects in certain immediate early genes together with mutations in the essential structural protein.

15 Background to the Invention

 Herpes viruses have been suggested as potential vectors for gene delivery. This could, for example, either be to the nervous system or elsewhere in the body for gene therapy, vaccine or other purposes, or to cells in culture or to animal models of disease. However,
20 while HSV has a number of potential advantages as a vector in that it can infect a wide variety of cell types *in vitro* and *in vivo* and can accept large DNA insertions allowing the delivery of multiple genes, infection of most cell types with HSV will result in lytic replication or other toxic effects of the virus. Thus for use as a vector HSV must usually be disabled in some way to prevent or minimise these effects.

25 HSV can be disabled in a number of ways, and this includes when used as a helper virus in the growth of so-called amplicon vectors which consist of plasmids containing herpes origin and packaging sequences which can be replicated in the presence of a helper virus after transfection into permissive cells. For example genes required for replication in all cell types can be inactivated, which must be complemented for growth in culture, these
30 including one or other or both of the essential immediate early genes ICP4 or ICP27. Alternatively genes required for pathogenesis *in vivo* but which are not required for growth

-2-

in culture can be removed, such as ICP34.5 or ICP6, as can further genes the deletion of which reduces toxicity further. These can for example include the other IE genes ICP0, ICP22, and ICP47, the inactivation of ICP0 and/or ICP22 reducing the efficiency of virus replication in culture unless these are also complemented in the cell line used for virus growth. The production of effective and practical vector viruses therefore depends on a balance of appropriately minimised toxicity in the target cell type, and on the ability to grow the virus in culture, in some cases requiring the use of a cell line complementing at least some of the inactivating mutations in the virus. As a general rule, the greater the number of mutations in the virus, the harder the virus will be to grow in culture. HSV vectors generally are reviewed in Coffin and Latchman, 1996.

It can be seen from the above that particularly attractive genes for inactivation in the production of HSV vectors are one or more of the five IE genes, as inactivation of these will for ICP0, ICP4, ICP22 or ICP27 at least, also reduce levels of other proteins the expression of which is stimulated by these IE gene products. However if these genes are inactivated replication in culture will either be blocked (ICP4 and ICP27) or reduced (ICP0 and ICP22), and thus for efficient replication the inactivated genes must be complemented in the cell line used for virus growth.

However an alternative means by which the levels of functional IE proteins can be reduced, rather than by including inactivating mutations in the IE genes themselves, is to include an inactivating mutation in the gene encoding VP16 (Ace *et al.*, 1988). VP16 is a virion protein that together with cellular factors is responsible for the trans-activation of HSV IE gene promoters after infection. Thus inclusion of specific inactivating mutations in VP16 results in a virus in which IE gene expression is reduced, although not blocked completely (Ace *et al.*, 1989). This may be advantageous in the production of an HSV vector virus as inactivation of a function in one gene (VP16) results in reduced levels of expression of multiple IE genes.

The gene for VP16 cannot however be deleted from the virus as it is also an essential structural protein. Specific mutations are therefore used which reduce or abolish the transactivating activity of VP16, but still allow the protein to fulfill its structural function (Ace *et al.*, 1988). Viruses including this type of mutation - specifically insertion of a linker sequence into the gene for VP16 as in virus mutant in1814 (Ace *et al.*, 1989) - are essentially

avirulent *in vivo*, giving reduced growth both *in vivo* and in culture (Ace *et al.*, 1989). Growth of stocks of viruses including such a mutation is thus of reduced efficiency as compared to viruses lacking the mutation. The mutation in VP16 can be partially compensated for by the inclusion of HMBA in the media (MacFarlane *et al.*, 1992), but cell lines cannot be used that have been engineered to express an unaltered copy of VP16 without the generation of virus in the culture in which the mutation has been repaired. This is because, as the gene cannot be deleted from the virus due to its essential structural role, the inclusion of an unaltered copy of the gene for VP16 in the cell line used for virus growth would result in the generation of virus containing the unaltered VP16 sequence by homologous recombination between the mutated VP16 sequence in the virus and the unaltered VP16 sequence in the cell line. Moreover complementation of the VP16 mutation by such a cell line would in any case result in the production of new virions containing fully functional VP16, which when used as a vector in non-complementing cells would activate IE gene expression, exactly as the mutation in VP16 was intended to reduce.

The problem therefore remains of how to efficiently grow stocks of HSV including mutations in the gene for VP16 which affect the trans-activating properties of the protein, such that the mutation in the virus cannot be repaired during virus growth.

Summary of the Invention

HSV with mutations in VP16 that reduce the trans-activating properties of the protein may be particularly attractive as vectors, particularly when combined with inactivating mutations in other HSV genes (see Coffin and Latchman, 1996). However such viruses cannot easily be efficiently grown in culture without repair of the mutation if a cell line complementing VP16 is used (see above). The main function of VP16, as well as its structural role, is to trans-activate HSV IE promoters after infection. We have found that not only can a protein with a similar role in another herpes virus, equine herpes virus 1 (EHV 1), trans-activate HSV IE promoters, but that it can also greatly enhance the growth of HSV with mutations in VP16 when stably transfected into the cells used for virus growth. There is little nucleotide sequence similarity between the EHV 1 equivalent of VP16 (Gene 12; see Lewis *et al.*, 1997, here termed EHV-VP16) and HSV-VP16, and thus homologous recombination

repairing the mutation in the virus is not possible. The invention thus for the first time provides cell lines which allow the efficient growth of HSV with mutations in VP16, reducing its transactivating properties, but in which repair of the mutation by homologous recombination is not possible.

5 The invention also provides a general methodology by which mutations in genes encoding essential structural polypeptides in HSV or homologous genes in other viruses can be complemented for growth in culture by the use of a protein with a homologous function in one virus to complement a deficiency in the equivalent protein in another. For example, HSV mutations in VP16 may be complemented using the EHV-VP16 equivalent (as here)
10 or the homologous protein from another herpes virus, e.g. BTIF from bovine herpes virus (BHV; Misra *et al.*, 1994), or the ORF10 gene product from varicella zoster virus (VZV; Moriuchi *et al.*, 1993).

 Accordingly, the present invention provides a process for propagating a mutant herpes virus having a mutation in its endogenous HSV VP16 gene or a homologue thereof, which
15 process comprises infecting a cell line with the mutant herpes virus and culturing the cell line, wherein the cell line comprises a nucleic acid sequence encoding a functional herpes simplex virus (HSV) VP16 polypeptide, or a homologue thereof, operably linked to a control sequence permitting expression of the polypeptide in said cell line; the nucleic acid sequence being (i) capable of complementing the endogenous gene and (ii) unable to recombine with
20 the endogenous gene.

 Preferably the mutation is a mutation which reduces or abolishes the ability of said endogenous gene to activate viral transcription

 Preferably, the functional HSV VP16 homologue is encoded by a herpes virus gene, more preferably an equine herpes virus gene, for example gene 12, or a bovine herpes virus
25 gene, for example BTIF. The mutant herpes virus is preferably a herpes simplex virus (HSV) more preferably an HSV-1 or HSV-2 virus or a derivative thereof.

 The mutant herpes virus may also comprise additional mutations which functionally inactivate additional genes of the virus and which need to be complemented by the cell line to allow viral growth in the cell line. In this case, the cell line will comprise additional
30 nucleic acid sequences encoding functional herpes virus genes that complement the endogenous genes that have been functionally inactivated. For example, in a preferred

embodiment, the mutant virus is a herpes simplex virus lacking functional essential immediate early genes such as ICP4 and/or ICP27. Consequently, the cell line of the invention will also comprise a functional ICP4 and/or ICP27 gene, as appropriate, to provide functional ICP4 and/or ICP27 thus allowing growth of the disabled virus in culture.

5 In particularly preferred embodiments the gene(s) for ICP4 and/or ICP27 are deleted from an HSV mutant also having the in1814 inactivating mutation in VP16 (Ace *et al.*, 1989). These mutants are grown on cell lines containing the EHV-VP16 gene and also the ICP4 and/or ICP27 genes, but with no overlap between the sequences inserted into the cell line and those remaining in the virus. This prevents repair of any of the mutations in the
10 virus by homologous recombination between sequences in the cell line and in the virus during virus growth. The inventors have found that in such embodiments promoter choice driving expression of ICP4 and ICP27 in the cells is important of the reliable generation of complementing cells containing EHV-VP16 and/or ICP27. The current invention thus also provides cell lines in which such promoter choice has been optimised. In such embodiments
15 it is preferred that ICP27 gene expression is driven by the ICP27 promoter and that ICP4 gene expression is driven by the ICP4 promoter or more preferably by the MMTV LTR promoter.

The mutant herpes viruses produced by the process of the invention may be isolated from the cultured cell line and, optionally, further purified. The viruses may also be
20 formulated as a pharmaceutical composition with a pharmaceutically acceptable carrier or diluent.

The present invention also provides a cell line comprising a nucleic acid sequence encoding a functional herpes simplex virus (HSV) VP16 polypeptide homologue, operably linked to a control sequence permitting expression of the polypeptide in said cell line, which
25 nucleic acid sequence is (i) capable of complementing an HSV VP16 gene and (ii) unable to recombine with the HSV VP16 gene.

Preferably, the functional HSV VP16 homologue is encoded by a herpes virus gene, more preferably an equine herpes virus gene, for example gene 12, or a bovine herpes virus gene, for example BTIF. The mutant herpes virus is preferably a herpes simplex virus (HSV)
30 more preferably an HSV-1 or HSV-2 virus or a derivative thereof.

Cell lines may also be produced in which other genes inactivated in the virus are complemented in the cell line for virus growth, together with (in the case of HSV) complementation of inactivating mutations in the gene for VP16 using the VP16 equivalent from another herpes virus. For example if either ICP4 and/or ICP27 are inactivated cell lines
5 also containing ICP4 and/or ICP27 may be used. In this embodiment promoter choice driving expression of ICP4 and ICP27 in the cells is important, the current invention thus also provides cell lines in which such promoter choice has been optimised. A preferred promoter for driving ICP27 gene expression in the ICP27 promoter and preferred promoters for driving ICP4 gene expression include the MMTV LTR and ICP4 promoters.

10

Detailed Description of the Invention

A. Herpes viruses

Herpes viruses include any virus that is a member of the family herpesviridae. This
15 includes equine herpes virus, bovine herpes virus and the human herpes simplex virus group, in particular HSV1 and HSV2.

When the virus of the invention is a herpes simplex virus, the virus may be derived from, for example, HSV1 or HSV2 strains, or derivatives thereof, preferably HSV1. Derivatives include inter-type recombinants containing DNA from HSV1 and HSV2 strains.
20 Derivatives preferably have at least 70% sequence homology to either the HSV1 or HSV2 genomes, more preferably at least 80%, even more preferably at least 90 or 95%. Other derivatives which may be used to obtain the viruses of the present invention include strains that already have mutations in genes, particularly mutations in genes that result in attenuation of the virus. Examples of such viruses include strain 1716 (MacLean *et al.*, 1991), strains
25 R3616 and R4009 (Chou and Roizman, 1992) and R930 (Chou *et al.*, 1994) all of which have mutations in ICP34.5, strain d120 which has a deletion in ICP4 (DeLuca *et al.*, 1985), strain d27-1 (Rice and Knipe, 1990) which has a deletion in ICP27) or strain d92 which has deletions in both ICP27 and ICP4 (Samaniego *et al.*, 1995).

The terminology used in describing the various HSV genes is as found in Coffin and
30 Latchman, 1996.

B. Mutations in structural genes

A mutant herpes virus in the context of the present invention typically has a mutation in a gene encoding an essential structural polypeptide that has a secondary non-structural function, for example transcriptional activation or enzymatic activity. The mutation will affect the secondary function of the protein, typically transcriptional activation, resulting in a reduction in the efficiency of virus growth, but without preventing the expression of the polypeptide thus allowing the polypeptide to fulfil its structural role. The mutation in said structural gene typically reduces or abolishes the ability of the polypeptide encoded by the gene to activate viral transcription, in particular transcription initiated from immediate early promoters. The reduction in viral transcription mediated by the structural polypeptide is generally at least 50%, more preferably at least 70, 80, or 90%.

In a preferred embodiment of the invention, the structural gene is the HSV gene encoding VP16 (UL48), or a homologue thereof found in a different herpes virus, for example equine herpes virus gene 12 or bovine herpes virus gene BTIF. The HSV VP16 gene typically has an insertion that abolishes its trans-activating ability (see, for example, Ace *et al.*, 1989). Other mutants with similar properties have also been described including a truncation of the acidic activation domain of HSV VP16 (e.g. see Smiley, J. R., and J. Duncan. 1997). Such mutants are also suitable for use in the invention.

By a "homologue" it is meant a virus gene that exhibits sequence homology, at the amino acid level, to the corresponding structural herpes virus gene which is mutated in the mutant herpes virus which it is desired to propagate. Typically, a homologue of, for example, an HSV gene will be at least 15%, preferably at least 20%, identical at the amino acid level to the corresponding HSV gene over a region of at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids. The homologue must be capable of complementing the function of the mutant endogenous gene present in the genome of the mutant herpes virus that it is desired to propagate. However, to avoid homologous recombination between the functional structural herpes virus gene present in the complementing cell line and the mutant gene present in the herpes virus genome, the functional gene should be no more than 50%, preferably no more than 40 or 30% identical at the nucleotide level, over the entire coding sequence to the corresponding mutant gene present in the herpes virus.

Methods of measuring protein and nucleotide homology are well known in the art and it will be understood by those of skill in the art that in the present context, protein homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology").

Methods of measuring nucleic acid and protein homology are well known in the art. Homology can be calculated using, for example, the UWGCG Package which provides the BESTFIT program which can be used to calculate homology (Devereux *et al* (1984) *Nucleic Acids Research* 12, p.387-395). Similarly, the PILEUP and BLAST algorithms can be used to line up sequences (for example as described in Altschul S. F. (1993) *J. Mol. Evol.* 36:290-300; Altschul, S. F. *et al* (1990) *J. Mol. Biol.* 215:403-10). Many different settings are possible for such programs. According to the invention, the default settings may be used.

Further, the sequence of the functional structural gene may be modified at the nucleotide level, for example by substitution, to reduce the degree of homology between the functional gene present in the cell line and the mutant gene present in the herpes virus to reduce further the possibility of recombination. This can be achieved without changing the amino acid sequence of the functional gene as a result of the degeneracy of the genetic code.

Conservative substitutions may also be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

Homologues of herpes virus genes from particular herpes viruses (for example HSV) can be identified in other viruses in a number of ways, for example by probing genomic or cDNA libraries made from other viruses with probes comprising all or part of the HSV gene under conditions of medium to high stringency (0.2X SSC/0.1% SDS at from about 40°C to about 55°C). Alternatively, species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences. The primers will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences (for example, 2 x SSC at 60°C).

In the case of HSV1 and HSV2 such strains particularly include mutations in the gene for VP16 (UL48) which abolish or reduce the trans-activating activity of the protein without affecting its structural role (see, for example, Ace *et al.*, 1988). These virus strains also include strains in which further mutations have been included, possibly requiring the use of cell lines also complementing these mutations e.g. ICP4 and/or ICP27 for HSV1 or their functional equivalents in HSV2, if one or other or both of these genes contain inactivating mutations. Preferred viruses include HSV1 or HSV2 containing mutations abolishing the transactivating function of VP16, together with the complete deletion of the genes for ICP4 and/or ICP27 (or equivalents in HSV2) such that there is no overlap between the DNA remaining in the virus and that in the cell line used for virus growth. Further inactivating mutations may also be made in the virus, for example in ICP34.5, vhs, and/or ICP6. A particularly preferred virus would include inactivating mutations in all of these genes.

The various other viral genes referred to may be rendered functionally inactive by several techniques well known in the art. For example, they may be rendered functionally inactive by deletions, substitutions or insertions, preferably by deletion. Deletions may remove portions of the genes or the entire gene. For example, deletion of only one nucleotide may be made, resulting in a frame shift. However, preferably larger deletions are made, for example at least 25%, more preferably at least 50% of the total coding and non-coding sequence (or alternatively, in absolute terms, at least 10 nucleotides, more preferably at least 100 nucleotides, most preferably, at least 1000 nucleotides). It is particularly preferred to remove the entire gene and some of the flanking sequences. Inserted sequences may include the heterologous genes described below. In particular, it is preferred to insert the

heterologous gene into ICP4.

In the case of the gene encoding an essential structural polypeptide, clearly it is not desirable to delete large portions of the gene. However, small deletions, insertions and/or substitutions may be made as appropriate to abrogate the desired activity, for example trans-
5 activation (see, for example, Ace *et al.*, 1989).

Mutations are made in the herpes viruses by homologous recombination methods well known to those skilled in the art. For example, HSV genomic DNA is transfected together with a vector, preferably a plasmid vector, comprising the mutated sequence flanked by homologous HSV sequences. The mutated sequence may comprise deletions, insertions
10 or substitutions, all of which may be constructed by routine techniques. Insertions may include selectable marker genes, for example lacZ, for screening recombinant viruses by, for example, β -galactosidase activity.

C. Heterologous genes and promoters

15 The viruses of the invention may carry a heterologous gene. The term "heterologous gene" encompasses any gene. Although a heterologous gene is typically a gene not present in the genome of a herpes virus, a herpes gene may be used provided that the coding sequence is not operably linked to the viral control sequences with which it is naturally associated. The heterologous gene may be any allelic variant of a wild-type gene, or it may
20 be a mutant gene. The term "gene" is intended to cover nucleic acid sequences which are capable of being at least transcribed. Thus, sequences encoding mRNA, tRNA and rRNA are included within this definition. Nucleic acids may be, for example, ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or analogues thereof. Sequences encoding mRNA will optionally include some or all of 5' and/or 3' transcribed but untranslated flanking sequences
25 naturally, or otherwise, associated with the translated coding sequence. It may optionally further include the associated transcriptional control sequences normally associated with the transcribed sequences, for example transcriptional stop signals, polyadenylation sites and downstream enhancer elements.

The heterologous gene may be inserted into the viral genome by homologous
30 recombination of HSV strains with, for example, plasmid vectors carrying the heterologous gene flanked by HSV sequences. The heterologous gene may be introduced into a suitable

plasmid vector comprising herpes viral sequences using cloning techniques well-known in the art. The heterologous gene may be inserted into the viral genome at any location provided that the virus can still be propagated. It is preferred that the heterologous gene is inserted into an essential gene.

5 The transcribed sequence of the heterologous gene is preferably operably linked to a control sequence permitting expression of the heterologous gene in mammalian cells, preferably cells of the central and peripheral nervous system. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding
10 sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequence.

 The control sequence comprises a promoter allowing expression of the heterologous gene and a signal for termination of transcription. The promoter is selected from promoters which are functional in mammalian, preferably human, cells. The promoter may be derived
15 from promoter sequences of eukaryotic genes. For example, it may be a promoter derived from the genome of a cell in which expression of the heterologous gene is to occur, preferably a cell of the mammalian central or peripheral nervous system. With respect to eukaryotic promoters, they may be promoters that function in a ubiquitous manner (such as promoters of α -actin, tubulin) or, alternatively, a tissue-specific manner (such as promoters
20 of the genes for pyruvate kinase). Promoters that are active in only certain neuronal cell types are especially preferred (for example the tyrosine hydroxylase (TH), L7, or neuron specific enolase (NSE) promoters). They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV
25 LTR), the promoter rous sarcoma virus (RSV) LTR promoter or the human cytomegalovirus (CMV) IE promoter.

 The HSV LAT promoter, and promoters containing elements of the LAT promoter region, may be especially preferred because there is the possibility of achieving long-term expression of heterologous genes during latency. In particular, an expression cassette
30 consisting essentially of a LAT P2 region, which does not itself here act as a promoter, linked to a promoter and a heterologous gene in that order is especially preferred (WO98/30707).

The term "long-term expression" is taken to mean expression of a heterologous gene in a cell infected with a herpes simplex virus of the invention even after the herpes simplex virus has entered latency. Preferably, this is for at least two weeks, more preferably at least one or two months after infection, even more preferably for the life-time of the cell.

5 Expression cassettes may further comprise a second promoter and a second heterologous gene operably linked in that order to said HSV LAT P2 region and in the opposite orientation to the first promoter and first heterologous gene wherein said second promoter and second heterologous gene are the same as or different to the first promoter and first heterologous gene. Thus a pair of promoter/heterologous gene constructs in opposite
10 orientations flank a single LAT P2 region allowing the long term expression of pairs of heterologous genes, which may be the same or different, driven by the same or different promoters. Furthermore, the product of the first heterologous gene may regulate the expression of the second heterologous gene (or vice-versa) under suitable physiological conditions.

15 Expression cassettes and other suitable constructs comprising the heterologous gene and control sequences can be made using routine cloning techniques known to persons skilled in the art (see, for example, Sambrook *et al.*, 1989, Molecular Cloning - a laboratory manual; Cold Spring Harbor Press). The LAT P2 region is here defined as HSV1 nucleotides 118866-120219 of HSV1 strain 17+ (GenBank HE1CG: from PstI-BstXI sites), fragments
20 or derivatives of this region, including homologous regions of other HSV1 strains and of HSV2, which are capable of providing a long-term expression capability to promoters to which they are linked.

It may also be advantageous for the promoters to be inducible so that the levels of expression of the heterologous gene can be regulated during the life-time of the cell.
25 Inducible means that the levels of expression obtained using the promoter can be regulated. For example, in a preferred embodiment where more than one heterologous gene is inserted into the HSV genome, one promoter would comprise a promoter responsive to the tet repressor/VP16 transcriptional activator fusion protein, and driving the heterologous gene the expression of which is to be regulated. The second promoter would comprise a strong
30 promoter (e.g. the CMV IE promoter) driving the expression of the tet repressor/VP16 fusion protein. Thus in this example expression of the first heterologous gene would depend on the

presence or absence of tetracycline.

In addition, any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences (including elements of the LAT region). Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above, for example an MMLV LTR/LAT fusion promoter (Lokensgard *et al.*, 1994) or promoters comprising elements of the LAT region (see above).

The heterologous gene may encode, for example, proteins involved in the regulation of cell division, for example mitogenic growth factors including neurotrophic growth factors (such as brain-derived neurotrophic factor, glial cell derived neurotrophic factor, NGF, NT3, NT4 and NT5, GAP43 and), cytokines (such as α , β or γ -interferon, interleukins including IL-1, IL-2, tumour necrosis factor, or insulin-like growth factors I or II), protein kinases (such as MAP kinase), protein phosphatases and cellular receptors for any of the above. The heterologous gene may also encode enzymes involved in cellular metabolic pathways, for example enzymes involved in amino acid biosynthesis or degradation (such as tyrosine hydroxylase or GTP - cyclohydrolase), purine or pyrimidine biosynthesis or degradation, and the biosynthesis or degradation of neurotransmitters, such as dopamine, or protein involved in the regulation of such pathways, for example protein kinases and phosphatases. The heterologous gene may also encode transcription factors or proteins involved in their regulation, for example members of the Brn3 family or pocket proteins of the Rb family such as Rb or p107, membrane proteins (such as rhodopsin), structural protein (such as dystrophin) or heat shock proteins such as hsp70.

Preferably, the heterologous gene encodes a polypeptide of therapeutic use. For example, of the proteins described above, tyrosine hydroxylase and glial cell derived neurotrophic factor can be used in the treatment of Parkinson's disease, rhodopsin can be used in the treatment of eye disorders, dystrophin may be used to treat muscular dystrophy, and heat shock proteins can be used to treat disorders of the heart and brain associated with ischaemic stress. Polypeptides of therapeutic use may also include cytotoxic polypeptides such as ricin, or enzymes capable of converting a precursor prodrug into a cytotoxic compound for use in, for example, methods of virus-directed enzyme prodrug therapy or gene-directed enzyme prodrug therapy. In the latter case, it may be desirable to ensure that

the enzyme has a suitable signal sequence for directing it to the cell surface, preferably a signal sequence that allows the enzyme to be exposed on the exterior of the cell surface whilst remaining anchored to cell membrane. Suitable enzymes include bacterial nitroreductase such as *E. coli* nitroreductase as disclosed in WO93/08288 or
5 carboxypeptidase, especially carboxypeptidase CPG2 as disclosed in WO88/07378. Other enzymes may be found by reference to EP-A-415731. Suitable prodrugs include nitrogen mustard prodrugs and other compounds such as those described in WO88/07378, WO89/10140, WO90/02729 and WO93/08288 which are incorporated herein by reference.

Heterologous genes may also encode antigenic polypeptides for use as vaccines.
10 Preferably such antigenic polypeptides are derived from pathogenic organisms, for example bacteria or viruses.

Heterologous genes may also include marker genes (for example encoding β -galactosidase or green fluorescent protein) or genes whose products regulate the expression of other genes (for example, transcriptional regulatory factors including the tet
15 repressor/VP16 transcriptional activator fusion protein described above).

Gene therapy and other therapeutic applications may well require the administration of multiple genes. The expression of multiple genes may be advantageous for the treatment of a variety of conditions. Herpes viruses are uniquely appropriate as they do not have the limited packaging capabilities of other viral vector systems. Thus multiple heterologous
20 genes can be accommodated within its genome. There are, for example, at least two ways in which this could be achieved. For example, more than one heterologous gene and associated control sequences could be introduced into a particular HSV strain. It would also be possible to use pairs of promoters (the same or different promoters) facing in opposite orientations away from a centrally located LAT P2 element, these promoters each driving the
25 expression of a heterologous gene (the same or different heterologous gene) as described above.

E. Complementing structural genes

The nucleic acid sequence present in the cell line of the invention, which encodes a
30 functional structural herpes virus polypeptide, will be able to complement in trans the activity of the corresponding mutated endogenous gene in the mutant herpes virus that it is desired

to propagate. Typically, the functional complementing gene will be a homologue of the mutant endogenous gene. The identification of suitable homologues, where not already known, is described above. However, as discussed above, the functional structural gene must be unable to recombine by homologous recombination with the mutant endogenous gene present in the mutant virus to repair the mutant endogenous gene. Thus the level of nucleotide homology between the two genes must be such that homologous recombination can not occur between the two sequences. The appropriate level of nucleotide homology required to achieve this is described above.

The functional structural gene will therefore typically originate from a different virus to the mutant endogenous gene, such as a different viral species. Thus, for example, where the mutant herpes virus is an HSV with a mutation in its endogenous VP16 gene, the functional gene will be a homologue of VP16 from a different virus, for example an equine herpes virus gene 12, a bovine herpes virus BTIF gene or a VZV ORF10 gene. A particularly preferred VP16 sequence is that encoding gene 12 from EHV1 (nts 13505-14944 of the complete EHV1 genome [GenBank file HSECOMGEN]).

Equally, where it is desired to propagate an equine or bovine herpes virus which as a mutation in its endogenous gene 12 or BTIG gene, respectively, the cell line may comprise a functional HSV VP16 coding sequence.

The coding sequence of the functional structural polypeptide is operably linked to a control sequence permitting expression of the polypeptide in a cell line of the invention. Cell lines of the invention are typically mammalian cells and therefore the control sequences will be regulatory sequences capable of functioning in mammalian cells. The control sequences may be constitutively active in the cell line or may be inducible. Suitable control sequences are described above.

25

F. Cell lines

Cell lines used in the invention include any cell line comprising a nucleic acid sequence encoding a functional structural herpes virus polypeptide, operably linked to a control sequence permitting expression of the polypeptide in the cell line. A suitable cell line is a cell line which hosts herpes viruses and forms colonies. Typically the cell line is a mammalian cell line such as a rodent or human cell line.

30

The functional structural herpes virus polypeptide is a polypeptide from one virus which can complement the growth of another virus in which the gene for the homologous polypeptide has been mutated. Preferred polypeptides perform an essential structural role in the virus, and also a second function the inactivation of which reduces the efficiency of virus growth. In the case of HSV1 or HSV2, preferred mutations include those of the type described by Ace *et al.*, 1988 or Smiley and Duncan, 1997 in the gene for VP16. Preferred cell lines of the invention thus containing a gene for the functional equivalents of VP16 from another viruses, for example gene 12 from EHV1, BTIF from BHV, or ORF10 from VZV.

Cell lines expressing a functional herpes virus structural polypeptide can be produced by standard methods such as co-transfecting mammalian cells, for example Vero or BHK cells, with a vector, preferably a plasmid vector, comprising a nucleic acid encoding the structural polypeptide, and a vector, preferably a plasmid vector, encoding a selectable marker, for example neomycin resistance. Clones possessing the selectable marker are then screened further to determine which clones also express functional polypeptide, for example on the basis of their ability to support the growth of VP16 mutant HSV strains, using methods known to those skilled in the art (for example as described in Rice and Knipe, 1990).

A particularly preferred cell line would be based on BHK or Vero cells, and contain the EHV1 gene 12 sequence together with the gene for ICP27 and/or ICP4 or equivalents from HSV2 allowing the propagation of HSV with an inactivating mutation in VP16, together with further inactivating mutations in the genes for ICP27 and/or ICP4. Preferably there would be no overlap between the DNA in the cell line and that remaining in the virus to be grown, preventing repair of the inactivating mutations in the virus to be grown by homologous recombination between DNA in the virus and DNA in the cell line.

Cell lines expressing ICP27 and/or ICP4 are known in the art, for example V27 cells (Rice and Knipe, 1990), B130/2 cells (WO98/30707) or used E26 cells (Samaniego *et al.*, 1995). These cell lines may be utilised to produce a cell line of the invention. However, as we have found promoter choice driving ICP4 and ICP27 to be important in such embodiments, the current invention also provides for cell lines in which such promoter choice has been optimised, by driving ICP4 expression from the ICP4 promoter or MMLV LTR promoter and ICP27 expression from the ICP27 promoter.

The invention will be described with reference to the following Examples which are intended to be illustrative only and not limiting.

EXAMPLES

5

HSV-1 nucleotide numbers referred to in the following examples refer to GenBank file HE1CG.

Example 1 EHV-VP16 can trans-induce HSV immediate early gene promoters.

10

CAT assays (by the method of Gorman 1985) were performed in which plasmid constructs with the chloramphenicol acetyl transferase gene under the control of either the HSV1 ICP4, ICP0 or ICP27 (pIGA102, pIGA65 and pIGA95 respectively; Gelman and Silverstein, 1987) were co-transfected into BHK cells together with either a control plasmid
15 (pcDNA3; Invitrogen), or similar plasmids into which either HSV-VP16 (pCMV16; Moriuchi *et al.*, 1995) or EHV-VP16 sequences had been inserted. 5 µg of each plasmid was used per transfection into 6 well plates. Experiments were performed in duplicate. The EHV-VP16 expression construct (pcDNA3/E) was constructed by insertion of the EHV-VP16 sequence into the EcoRV and XbaI sites of pcDNA3 (Invitrogen) after release from
20 pcDNA1/amp by digestion with EcoRI and XbaI into which it had originally been cloned.

Results

Results are shown as the % conversion of the ¹⁴C-labelled chloramphenicol from the non-acetylted to acetylated forms by phosphorimagery of resulting TLC plates. The results
25 of each duplicate experiment are shown.

Test promoter	Activator	% conversion
ICP0	control	31, 33
ICP0	HSV-VP16	83, 83
ICP0	EHV-VP16	82, 84
ICP27	control	15, 16
ICP27	HSV-VP16	44, 38
ICP27	EHV-VP16	27, 34
ICP4	control	34, 30
ICP4	HSV-VP16	75, 76
ICP4	EHV-VP16	75, 63

These results showed that EHV-VP16 could trans-activate HSV 1 IE promoters to a similar degree to HSV-VP16 for the ICP0 and ICP4 promoters, and somewhat less so for the ICP27 promoter, which is in any case less responsive to HSV-VP16 than are the other two promoters tested. This suggested that EHV-VP16 might functionally complement HSV-VP16 mutants such as in1814 (Ace *et al.*, 1989) in which the trans-activating activity has been reduced, if expressed in the cells used for virus growth, providing cell lines in which such viruses could be more efficiently propagated.

Example 2: Cell lines containing EHV-VP16 allow enhanced growth of HSV with an inactivating mutation in VP16

Experiments were performed to determine whether cell lines containing EHV-VP16 could complement deficiencies in virus growth caused by mutations to the VP16 gene which otherwise prevent efficient trans-activation of IE promoters and thus give poor virus growth.

BHK cells (grown in DMEM + 10% FCS, both Gibco, at 37°C/5%CO₂) were transfected (by the method of Gorman, 1985) in 10cm plates with plasmids containing either only a neomycin (neo) resistance selectable marker gene (pcDNA3), or neo together EHV-VP16 under the control of a CMV promoter and BGHpA sequence (pcDNA3/E). After transfection, G418 (800 µg/ml; Gibco) was used to kill non-stably transfected cells and plates allowed to grow over. Cells were then trypsinised into 24 well plates to allow growth to be assessed with virus mutants and wild type control virus. This procedure allowed the 'average' effect on the mutants tested of the EHV-VP16 gene and the control (neo only), without the clonal variation which would have occurred if colonies resulting from single transfectants

had been cloned in each case. Results show the total virus yield/well 24 hrs after infection at a multiplicity of infection MOI of 0.01. Experiments were performed in duplicate either with or without the inclusion of HMBA (3 mM) in the media (MacFarlane *et al.*, 1992).

5 Virus 17+ is a wild type virus, in1814 contains an inactivating mutation in VP16 (Ace *et al.* 1989), and virus 1764 contains the inactivating mutation in VP16 together with deletion of both copies of ICP34.5, which does not itself significantly effect the growth of HSV in BHK cells (see Coffin *et al.*, 1996).

10 Results:

Virus under test	Plasmid transfected	Yield + HMBA	Yield - HMBA
17+	neo	150000/ 250000	400000/ 250000
15 in1814	neo	10000/15000	1000/1500
	EHV-VP16	200000/90000	80000/65000
1764	neo	35000/45000	5000/4500
	EHV-VP16	400000/300000	100000/250000

20

These results showed that EHV-VP16 can complement the deficiency in virus growth caused by the inclusion of inactivating mutations in the gene for VP16, such as in virus in1814 (Ace *et al.*, 1989). Such viruses can be grown to near wild type levels, the level of complementation being greater than that achieved by the inclusion of HMBA in the media which has previously been reported to increase the efficiency of growth of HSV with mutations in VP16 (MacFarlane *et al.*, 1992).

25

Example 3: Cell lines containing EHV-VP16 and ICP27 give enhanced growth of HSV mutants deficient in VP16 and ICP27.

30

BHK cell lines prepared by the methods above were cloned out after transfection with only an ICP27 containing plasmid (the ICP27 coding sequence promoter and polyA excised from pSG130BS [Sekulovich *et al* 1988] with SacI and SphI inserted between the EcoRI and

Sall sites in pPGKneo [Soriano et al 1991]) or the ICP27 containing plasmid together with pcDNA3/E. This showed that in most cases better growth (as assessed by growth curves) could be obtained of viruses deficient in both ICP27 and vmw65 (VP16; HSV1 mutant 1764/27-/pR20) using clones resulting from the dual transfection. These experiments also
5 showed considerably larger plaques when HSV1 mutants inactivated for vmw65 (VP16), with or without deletion of ICP27, were grown on cells containing EHV gene 12.

Virus 1764/27-/pR20 contains an HSV1 LAT (nts 118,866-120,219[PstI-BstXI])/CMV/lacZ cassette inserted so as to delete the entire ICP27 coding sequence, UL55, UL56 (both non-essential genes; Roizman, R. and A. Sears. 1996) and part of the LAT region
10 in virus strain 1764 (Coffin et al, 1996) using flanking regions (nts 110,095-113,229 [EcoRI-NdeI] and 120,468-125,068 [HpaI-SacI] separated by a unique BglII site) and the selection and purification of X-gal staining plaques on B130/2 cells (Howard et al, 1998).

**Example 4: Promoter choice driving ICP4 is important in the generation of cell
15 lines giving effective growth of HSV mutants deficient in VP16, ICP27 and ICP4.**

Here cell lines capable of allowing the effective growth of viruses with VP16 deficiencies and in which both ICP27 and ICP4 were also deleted were generated.

We have found, as described above, that the ICP27 promoter driving ICP27 provides
20 effective cell lines complementing viruses deleted for ICP27 when the cells also contain EHV gene 12. Thus it was anticipated that the ICP27 promoter might also provide optimal regulation of ICP4 in cells complementing VP16, ICP27 and ICP4. Hence cell lines were produced in which ICP4 under ICP27 promoter and poly-A control in a plasmid encoding phleomycin resistance (plasmid p27/4zeo) was transfected into cells which already
25 effectively allowed the propagation of viruses which lacked ICP27 and were deficient in VP16 (cell lines generated in Example 3 above). Phleomycin/neomycin resistant colonies were picked and cloned out. However these were generally found to give only very poor growth of HSV-1 mutants deficient in VP16, ICP27 and ICP4 (virus 1764/27-/4-/pR20.5), with only 5 out of 140 colonies picked giving significant growth. Plasmid p27/4zeo was
30 constructed by replacing the ICP4 promoter in plasmid p4/2zeo (upstream of the BstEII site [HSV-1 nt 131,187]; see below) by a BamHI-DrdI (HSV-1 nts 113,322-113,728) promoter

fragment from pSG130BS. The ICP4 Poly A sequence was replaced by removal of sequences after the MseI site (HSV-1 nt 127,167) which were replaced with an EcoNI-SacI (HSV-1 nts 115,267-115,743) fragment from pSG130BS, encoding the ICP27 poly A Sequence.

5 Virus strain 1764/27-/4-/pR20.5 was constructed by insertion of a cassette consisting of GFP (E-GFP; Clontech) and lacZ driven by CMV and RSV promoters respectively in a back-to-back orientation and separated by HSV-1 LAT sequences (PstI-BstXI as in Example 3) into ICP4 flanking regions (HSV-1 nts 123,459-126,774 [Sau3aI-Sau3aI] and 131,730-134,792 [SphI-KpnI] with nts 124,945-125,723 [NotI-NotI; encodes ICP34.5] deleted
10 separated by unique XbaI and SalI sites in plasmid pDICP4) and recombination into virus strain 1764/27-w (virus strain 1764/27-/pR20 with the lacZ insertion removed by recombination with empty ICP27 flanking regions) using B4/27 cells which complement both ICP27 and ICP4. X-gal staining/green fluorescent plaques were selected and further purified. Cell line B4/27 was prepared by co-transfection of pSG130BS, plasmid p4/2 (see
15 below) and pMAMneo (Invitrogen) into BHK cells. Neomycin resistant clones were then selected.

Following these disappointing results other promoters were tested driving ICP4. Thus further phleomycin/neomycin resistant cell lines were produced in which ICP4 was driven either by the ICP4 promoter and poly A (using plasmid p4/2zeo) or by the
20 dexamethasone inducible MMTV promoter and an SV40 poly A (using plasmid pMAMzeo/ICP4). Here it was hoped that either correct regulation of ICP4 expression by the ICP4 promoter or dexamethasone inducible ICP4 expression might provide cell lines capable of improved growth of HSV-1 mutants deficient for VP16, ICP27 and ICP4.

For construction of p4/2zeo a phleomycin resistance gene cassette was excised from
25 plasmid pVgRxR (Invitrogen) as a BamHI fragment and inserted into the unique BglII site of plasmid p4/2 giving plasmid p4/2zeo. p4/2 contains the ICP4 promoter, coding region and polyA (HSV-1 nts 126,764-131,730 [DdeI-SphI]) inserted into pSP72 (Promega). For construction of pMAMzeo/ICP4 the neomycin resistance gene (excised as a BamHI fragment) in plasmid pMAMneo (Invitrogen) was replaced by the phleomycin resistance
30 gene as above, again as a BamHI fragment. The ICP4 coding region (HSV-1 nts 127,167-131,187 [MseI-BstEII]) was then inserted after the MMTV promoter at the XhoI site.

138 and 88 clones using the ICP4 and MMTV promoter respectively were picked and virus growth characteristics analysed. Of the ICP4 promoter driven clones, the majority were of only limited permissivity for the VP16/ICP27/ICP4 deficient virus, although two clones were capable of giving efficient growth. It was thought that this variability probably reflected positional effects altering the regulation of the ICP4 promoter in the context of EHV gene 12 expressing cells, in some rare cases allowing efficient growth of the VP16/ICP27/ICP4 deficient virus. However of the clones picked in which ICP4 was controlled by the MMTV promoter, 60 out of 88 gave efficient growth, at least as good as growth on the two ICP4 promoter containing cell lines. This indicated that with the MMTV promoter positional effects are of minimal importance for effective ICP4 regulation in the context of EHV gene 12 containing cell lines, unlike when the ICP4 promoter is used. However, inclusion of dexamethasone in the media at the time of inoculation using cells containing ICP4 under MMTV promoter control did not increase the yield of the VP16/ICP27/ICP4 deficient virus.

15 References

- Ace CI *et al.* (1988) J. Gen. Virol., 69, 2595-2605.
- Coffin RS and Latchman DS (1996). In: Genetic Manipulation of the Nervous System (DS Latchman Ed.) pp 99-114: Academic Press, London.
- 20 Ace CI *et al.* (1989) J. Virol., 63, 2260-2269.
- MacFarlane M, *et al.* (1992) J. Gen. Virol., 73, 285-292.
- Lewis JB, *et al.* (1997) Virology, 230, 369-375.
- Misra V, *et al.* (1994) J. Virol., 68, 4898-4909.
- Moriuchi H, *et al.* (1993) J. Virol., 67, 2739-2746.
- 25 Coffin RS, *et al.* (1996) Gene Therapy, 3, 886-891.
- Gorman CM (1985) In: DNA cloning, a practical approach. Glover DM (Ed). IRL Press, pp 143-190.
- Moriuchi H, *et al.* (1995) J. Virol., 69, 4693-4701.
- Gelman IH and Silverstein S (1987) J. Virol., 61, 2286-2296.
- 30 Samaniego LA *et al.* J. Virol. (1995); 69: 5705-5715
- MacLean AR *et al.* (1991), J Gen Virol 72: 632-639.

- Chou, J *et al.* (1994), J. Virol. 68: 8304-8311.
- Chou J and Roizmann B (1992), PNAS 89: 3266-3270.
- Rice, SA and Knipe DM. (1990), J. Virol 64: 1704-1715.
- DeLuca NA *et al.* (1985), J. Virol., 56: 558-570.
- 5 Lokensgard JR, *et al.* (1994) J. Virol., 68, 7148-7158.
- Smiley, J. R., and J. Duncan. 1997. J. Virol. 71: 6191-6193.
- Soriano, P., C. Montgomery, R. Geske, and A. Bradley. 1991. Cell 64:693-702.
- Sekulovich, R. E., K. Leary, and R. M. Sandri-Goldin. 1988. J. Virol. 62: 4510-4522.
- Roizman, R. and A. Sears. 1996. In Fields, B. N., D. M. Knipe, and P. M. Howley (eds.),
- 10 Fields Virology. Lippincott-Raven Publishers, Philadelphia.
- Howard, M. K *et al.*, 1998. Gene Therapy 5: 1137-1147.

CLAIMS

1. A process for propagating a mutant herpes virus having a mutation in its endogenous HSV VP16 gene or a homologue thereof, which process comprises infecting a cell line with the mutant herpes virus and culturing the cell line, wherein the cell line comprises a nucleic acid sequence encoding a functional herpes simplex virus (HSV) VP16 polypeptide, or a homologue thereof, operably linked to a control sequence permitting expression of the polypeptide in said cell line; the nucleic acid sequence being (i) capable of complementing the endogenous gene and (ii) unable to undergo homologous recombination with the endogenous gene.
2. A process according to claim 1 wherein the mutation reduces or abolishes the ability of said endogenous gene to activate viral transcription
3. A process according to claim 2 wherein the functional HSV VP16 homologue is encoded by a herpes virus gene selected from a bovine herpes virus gene and an equine herpes virus gene.
4. A process according to claim 3 in which the herpes virus gene is equine herpes virus 1 gene 12, or the bovine herpes virus gene BTIF.
5. A process according to any one of the preceding claims wherein the control sequence comprises a constitutively active promoter or an inducible promoter.
6. A process according to any one of the preceding claims wherein the mutant herpes virus is a herpes simplex virus (HSV).
7. A process according to claim 6 wherein the HSV is an HSV-1 or HSV-2.
8. A process according to any one of the preceding claims wherein the mutant herpes virus comprises additional mutations which functionally inactivate one or more additional

endogenous genes of said virus and the cell line comprises additional nucleic acid sequences encoding functional herpes virus genes which complement said additional functionally inactive endogenous genes.

9. A process according to claim 8 wherein said additional nucleic acid sequences encode HSV-1 ICP27 and/or ICP4, or equivalents thereof in HSV-2 or another herpes virus.

10. A process according to claim 9 in which HSV-1 ICP27 or equivalent thereof is driven by the ICP27 promoter and/or in which HSV-1 ICP4 or equivalent thereof is driven by the MMTV LTR promoter.

11. A process according to any one of the preceding claims further comprising isolating mutant herpes virus from the cultured cell line, and optionally purifying the mutant herpes virus.

12. A process according to claim 11 further comprising the step of formulating the mutant herpes virus as a pharmaceutical composition with a pharmaceutically acceptable carrier or diluent.

13. Use of a cell line as defined in any one of claims 1, 3 to 5, 8, 9 or 10 to propagate a mutant herpes virus as defined in any one of claims 1, 2, 6 or 7.

14. A cell line as defined in any one of claims 1, 3 to 5, 8, 9 or 10.

15. A virus obtained by a process according to any one of claims 1 to 11.

16. A pharmaceutical composition obtained by a process according to claim 12.

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/86, 5/10, A61K 48/00	A3	(11) International Publication Number: WO 00/08194 (43) International Publication Date: 17 February 2000 (17.02.00)
(21) International Application Number: PCT/GB99/02547 (22) International Filing Date: 3 August 1999 (03.08.99) (30) Priority Data: 9816856.0 3 August 1998 (03.08.98) GB (71) Applicant (for all designated States except US): NEUROVEX LIMITED [GB/GB]; Marquis House, 67-68 Jermyn Street, London SW1Y 6NY (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): COFFIN, Robert, Stuart [GB/GB]; UCL Medical School, Division of Pathology, Department of Molecular Pathology, The Windeyer Building, 46 Cleveland Street, London W1P 6DP (GB). LATCHMAN, David, Seymour [GB/GB]; UCL Medical School, Division of Pathology, Department of Molecular Pathology, The Windeyer Building, 46 Cleveland Street, London W1P 6DP (GB). (74) Agents: WOODS, Geoffrey; Corlett et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 25 May 2000 (25.05.00)
(54) Title: CELL LINES FOR THE PROPAGATION OF MUTATED HERPES VIRUSES (57) Abstract <p>A process for propagating a mutant herpes virus having a mutation in its endogenous HSV VP16 gene or a homologue thereof, which process comprises infecting a cell line with the mutant herpes virus and culturing the cell line, wherein the cell line comprises a nucleic acid sequence encoding a functional herpes simplex virus (HSV) VP16 polypeptide, or a homologue thereof, operably linked to a control sequence permitting expression of the polypeptide in said cell line; the nucleic acid sequence being (i) capable of complementing the endogenous gene and (ii) unable to undergo homologous recombination with the endogenous gene. In addition, the present invention provides cell lines which can be used for the growth of mutant herpes viruses which have defects in certain immediate early genes together with mutations in VP16 or homologue thereof.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PCT/GB 99/02547

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/86 C12N5/10 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WEINHEIMER S. P. ET AL.: "deletion of the VP16 open reading frame of Herpes Simplex Virus Type 1." JOURNAL OF VIROLOGY, vol. 66, no. 1, 1992, pages 258-269, XP002130926	1,2,5-8, 11-16
Y	the whole document	9,10
Y	WO 98 04726 A (BROWN SUZANNE MOIRA ;MACLEAN ALASDAIR RODERICK (GB); MEDICAL RES C) 5 February 1998 (1998-02-05)	9,10
A	the whole document	1-8, 11-16
A	WO 97 36481 A (CORBEAU PIERRE ;KRAUS GUNTER (US); UNIV CALIFORNIA (US); WONG STAA) 9 October 1997 (1997-10-09) page 9, line 17 - line 28	1-16

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

7. document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

¹ Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"a" document member of the same patent family

Date of the actual completion of the international search

18 February 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,
Fax: (+31-70) 340-9016

Date of mailing of the international search report

07/03/2000

Authorized officer

Mand1, B

INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/GB 99/02547

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LACHMANN R. H. ET AL.: "THE USE OF HERPES SIMPLEX VIRUS-BASED VECTORS FOR GENE DELIVERY TO THE NERVOUS SYSTEM" MOLECULAR MEDICINE TODAY, September 1997 (1997-09), pages 404-411, XP000783616 ISSN: 1357-4310 page 406, right-hand column, last paragraph	1-16
T	THOMAS S. K. ET AL.: "EQUINE HERPESVIRUS 1 GENE 12 CAN SUBSTITUTE FOR VMW65 IN THE GROWTH OF HERPES SIMPLEX VIRUS (HSV) TYPE 1 ALLOWING THE GENERATION OF OPTIMIZED CELL LINES FOR THE PROPAGATION OF HSV VECTORS WITH MULTIPLE IMMEDIATE-EARLY GENE DEFECTS" JOURNAL OF VIROLOGY, vol. 73, no. 9, September 1999 (1999-09), pages 7399-7409, XP002130927 the whole document	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/02547

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W0 9804726 A	05-02-1998	AU 3700797 A EP 0920523 A	20-02-1998 09-06-1999
W0 9736481 A	09-10-1997	AU 2721997 A CA 2249349 A EP 0903981 A	22-10-1997 09-10-1997 31-03-1999